Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
CKn9R326XpUgEUHj